Therapeutic Approach

Archive: 2015

Ritter Pharmaceuticals Enters Into a $10 Million Common Stock Purchase Agreement with Aspire Capital Fund

LOS ANGELES (December 21, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has entered into a $10 million common stock purchase agreement (the “Purchase Agreement”) and a registration rights agreement […]

Leave Your Comments »

Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update

LOS ANGELES (November 17, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the third quarter ended September 30, 2015. Recent Highlights – Closed initial public […]

Leave Your Comments »

Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board

LOS ANGELES (October 21, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the appointment of William J. Sandborn, M.D. to its Medical Advisory Board. Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals, commented, ”We are excited […]

Leave Your Comments »

Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer

LOS ANGELES (October 6, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the appointment of AnnKatrin Petersen-Jappelli, M.D., M.Sc. as its Chief Medical Officer. Michael D. Step, Chief Executive Officer of Ritter […]

Leave Your Comments »

Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference

LOS ANGELES (October 6, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 2015 Aegis Growth Conference on Thursday, October […]

Leave Your Comments »

Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum

LOS ANGELES (September 8, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (Ritter), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, will participate in the 3rd Microbiome R&D Business Collaboration Forum to be held September 10-11, 2015 […]

Leave Your Comments »

Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor

LOS ANGELES (August 5, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that William (Bill) Merino has been retained as a senior clinical and regulatory advisor to the company. Dr. Merino has extensive experience with the U.S. […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering

LOS ANGELES, June 29, 2015 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the closing of its previously announced initial public offering of 4,000,000 shares […]

Leave Your Comments »

Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors

LOS ANGELES (April 22, 2015) – Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Gerald T. Proehl has joined the Company’s Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will […]

Leave Your Comments »

Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors

LOS ANGELES (April 14, 2015) – Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company’s Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company’s […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD